EMA's Updated Guidance On Monitoring Off-Label Use Of Medicines Expected By Year End
This article was originally published in SRA
The European Medicines Agency is expected to finalize by the end of this year revisions to its policy on how drug companies should record and report off-label use of medicines not associated with an adverse reaction.
You may also be interested in...
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.